Pcn2 - Effectiveness and Safety of Pembrolizumab in Advanced or Metastatic Melanoma: Preliminary Results From Real World

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.085
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn4 - Effectiveness and Safety of Pembrolizumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Effectiveness and Safety of Nivolumab in the Treatment of Lung Cancer Patients in France: Preliminary Results From the Real-World EVIDENS Study

OncoImmunology
OncologyAllergyImmunology
2020English

Pcn138 - Cost-Effectiveness Analysis of Pembrolizumab in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Cancer in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

JAMA Oncology
Cancer ResearchOncology
2019English

Panhypopituitarism in Metastatic Melanoma Patient Treated With Ipilimumab and Pembrolizumab

Journal of Cutaneous Immunology and Allergy
2019English

Real-World Comparative Effectiveness of Second-Line Ipilimumab for Metastatic Melanoma: A Population-Based Cohort Study in Ontario, Canada

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Pembrolizumab in the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Trial Evidence and Experience

Therapeutic Advances in Urology
Urology
2019English

Pembrolizumab as First-Line Treatment for Metastatic Uveal Melanoma

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Effectiveness and Safety of Ipilimumab Therapy in Advanced Melanoma: Evidence From Clinical Practice Sites in the US

Journal of Community and Supportive Oncology
OncologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy